Cumberland Pharmaceuticals Inc. (CPIX) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
32.96
↑+41% vs avg
5yr avg: 23.36
30Y Low3.4·High61.1
P/FCF
↑
17.26
↑+105% vs avg
5yr avg: 8.40
30Y Low4.5·High31.2
P/B Ratio
↑
3.39
↑+132% vs avg
5yr avg: 1.46
30Y Low0.9·High3.4
ROE
↓
-12.0%
↓+23% vs avg
5yr avg: -15.7%
30Y Low-25%·High51%
Debt/EBITDA
4.08
+0% vs avg
5yr avg: 4.08
30Y Low0.4·High4.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CPIX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cumberland Pharmaceuticals Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 17.3x P/FCF, 105% above the 5-year average of 8.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $83M | $60M | $33M | $26M | $33M | $70M | $45M | $79M | $94M | $117M | $89M |
| Enterprise Value | $82M | $58M | $36M | $26M | $34M | $59M | $39M | $73M | $86M | $81M | $59M |
| P/E Ratio → | -29.32 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.87 | 1.34 | 0.88 | 0.65 | 0.78 | 1.93 | 1.19 | 2.31 | 2.31 | 2.85 | 2.70 |
| P/B Ratio | 3.39 | 2.43 | 1.48 | 0.87 | 0.91 | 1.63 | 0.95 | 1.55 | 1.69 | 1.83 | 1.22 |
| P/FCF | 17.26 | 12.31 | — | 4.54 | 5.14 | 11.62 | 13.55 | 28.22 | — | — | — |
| P/OCF | 16.92 | 12.07 | — | 4.20 | 3.88 | 10.97 | 8.26 | 25.94 | 30.25 | — | 156.81 |
P/E links to full P/E history page with 30-year chart
CPIX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Cumberland Pharmaceuticals Inc.'s enterprise value stands at 33.0x EBITDA, 41% above its 5-year average of 23.4x. The Healthcare sector median is 14.2x, placing the stock at a 132% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.31 | 0.95 | 0.65 | 0.81 | 1.63 | 1.05 | 2.11 | 2.12 | 1.98 | 1.78 |
| EV / EBITDA | 32.96 | 23.36 | — | — | — | — | — | — | — | — | 61.10 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 12.05 | — | 4.56 | 5.32 | 9.79 | 11.89 | 25.83 | — | — | — |
CPIX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cumberland Pharmaceuticals Inc. earns an operating margin of -6.3%. Operating margins have expanded from -24.2% to -6.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -12.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.0% | 85.0% | 82.6% | 84.7% | 78.3% | 75.5% | 76.9% | 78.4% | 81.9% | 82.1% | 82.0% |
| Operating Margin | -6.3% | -6.3% | -17.0% | -24.2% | -13.6% | -21.3% | -17.0% | -27.0% | -18.1% | -9.9% | -4.3% |
| Net Profit Margin | -6.4% | -6.4% | -17.1% | -15.9% | -13.3% | -9.7% | -8.9% | -10.3% | -17.1% | -19.4% | -2.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.0% | -12.0% | -25.0% | -19.3% | -14.2% | -7.8% | -6.8% | -6.6% | -11.7% | -11.6% | -1.3% |
| ROA | -3.7% | -3.7% | -8.2% | -7.2% | -6.3% | -3.9% | -3.3% | -3.3% | -6.8% | -8.5% | -1.0% |
| ROIC | -8.6% | -8.6% | -17.7% | -21.5% | -12.4% | -15.8% | -11.2% | -15.1% | -14.6% | -8.6% | -2.6% |
| ROCE | -6.6% | -6.6% | -13.2% | -16.2% | -8.8% | -11.3% | -8.4% | -11.2% | -9.2% | -5.3% | -1.8% |
CPIX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Cumberland Pharmaceuticals Inc. carries a Debt/EBITDA ratio of 4.1x, which is highly leveraged (27% above the sector average of 3.2x). The company holds a net cash position — cash of $11M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 0.91 | 0.63 | 0.58 | 0.38 | 0.41 | 0.42 | 0.36 | 0.15 | 0.06 |
| Debt / EBITDA | 4.08 | 4.08 | — | — | — | — | — | — | — | — | 4.25 |
| Net Debt / Equity | — | -0.05 | 0.12 | 0.00 | 0.03 | -0.26 | -0.12 | -0.13 | -0.14 | -0.56 | -0.42 |
| Net Debt / EBITDA | -0.51 | -0.51 | — | — | — | — | — | — | — | — | -31.55 |
| Debt / FCF | — | -0.26 | — | 0.02 | 0.19 | -1.83 | -1.66 | -2.39 | — | — | — |
| Interest Coverage | -5.63 | -5.63 | -9.68 | -8.41 | -8.52 | -55.74 | -23.92 | -36.74 | -54.17 | -40.71 | -11.55 |
Net cash position: cash ($11M) exceeds total debt ($10M)
CPIX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.01x means Cumberland Pharmaceuticals Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.28x to 1.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.01 | 1.01 | 1.15 | 1.28 | 1.60 | 2.37 | 1.95 | 2.08 | 2.69 | 3.88 | 4.43 |
| Quick Ratio | 0.84 | 0.84 | 1.03 | 1.11 | 1.26 | 1.93 | 1.53 | 1.71 | 1.69 | 3.50 | 4.07 |
| Cash Ratio | 0.31 | 0.31 | 0.57 | 0.65 | 0.69 | 1.40 | 0.96 | 1.17 | 1.30 | 2.83 | 3.39 |
| Asset Turnover | — | 0.58 | 0.50 | 0.48 | 0.45 | 0.43 | 0.39 | 0.33 | 0.36 | 0.44 | 0.35 |
| Inventory Turnover | 1.07 | 1.07 | 1.65 | 1.32 | 0.92 | 1.05 | 0.81 | 0.84 | 0.27 | 1.09 | 1.11 |
| Days Sales Outstanding | — | 138.92 | 112.79 | 90.05 | 114.37 | 69.76 | 120.67 | 83.42 | 70.28 | 74.46 | 81.01 |
CPIX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cumberland Pharmaceuticals Inc. returns 0.3% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 5.8% | 8.1% | — | 22.0% | 19.5% | 8.6% | 7.4% | 3.5% | — | — | — |
| Buyback Yield | 0.3% | 0.4% | 1.7% | 2.9% | 3.2% | 2.0% | 4.1% | 4.4% | 3.1% | 3.2% | 2.8% |
| Total Shareholder Yield | 0.3% | 0.4% | 1.7% | 2.9% | 3.2% | 2.0% | 4.1% | 4.4% | 3.1% | 3.2% | 2.8% |
| Shares Outstanding | — | $15M | $14M | $14M | $15M | $15M | $15M | $15M | $16M | $16M | $16M |
Peer Comparison
Compare CPIX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CPIXYou | $83M | -29.3 | 33.0 | 17.3 | 85.0% | -6.3% | -12.0% | -8.6% | 4.1 |
 HROW | $2B | -302.9 | 30.6 | 36.8 | 75.1% | 14.2% | -8.5% | 12.0% | 4.4 |
 PRPH | $369487 | -0.0 | — | — | 31.9% | -415.4% | -271.5% | -62.5% | — |
 AYTU | $18M | -1.0 | — | — | 69.0% | -11.8% | -58.1% | -33.5% | — |
 CODA | $109M | 26.1 | 13.6 | 18.0 | 66.5% | 17.1% | 7.4% | 11.2% | 0.1 |
 AMRX | $5B | 73.2 | — | 18.8 | 36.9% | -0.2% | 15.7% | -0.2% | — |
 LXRX | $955M | -15.4 | — | — | 99.4% | -98.2% | -39.7% | -22.7% | — |
 PCRX | $893M | 141.9 | 9.6 | 6.5 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PAHC | $1B | 26.1 | 12.5 | 30.1 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 ETON | $896M | -192.5 | 219.0 | 87.9 | 53.5% | 0.1% | -18.2% | 0.2% | 7.5 |
 KALA | $78M | -1.1 | — | — | — | — | -279.2% | — | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CPIX — Frequently Asked Questions
Quick answers to the most common questions about buying CPIX stock.
What is Cumberland Pharmaceuticals Inc.'s P/E ratio?
Cumberland Pharmaceuticals Inc.'s current P/E ratio is -29.3x. The historical average is 56.2x.
What is Cumberland Pharmaceuticals Inc.'s EV/EBITDA?
Cumberland Pharmaceuticals Inc.'s current EV/EBITDA is 33.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.6x.
What is Cumberland Pharmaceuticals Inc.'s ROE?
Cumberland Pharmaceuticals Inc.'s return on equity (ROE) is -12.0%. The historical average is 2.3%.
Is CPIX stock overvalued?
Based on historical data, Cumberland Pharmaceuticals Inc. is trading at a P/E of -29.3x. Compare with industry peers and growth rates for a complete picture.
What are Cumberland Pharmaceuticals Inc.'s profit margins?
Cumberland Pharmaceuticals Inc. has 85.0% gross margin and -6.3% operating margin.
How much debt does Cumberland Pharmaceuticals Inc. have?
Cumberland Pharmaceuticals Inc.'s Debt/EBITDA ratio is 4.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.